Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.
about
Clinical modalities for management of gastric cancer hepatic metastasisTargeting the function of the HER2 oncogene in human cancer therapeutics.Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma.An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.Simultaneous detection of expression and gene mutations of HER2/neu in Chinese patients with gastric cancerIdentifying therapeutic targets in gastric cancer: the current status and future directionRadiation-induced EGFR-signaling and control of DNA-damage repair.The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas.The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.The Fra-1-miR-134-SDS22 feedback loop amplifies ERK/JNK signaling and reduces chemosensitivity in ovarian cancer cells.Anti-HER agents in gastric cancer: from bench to bedside.The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer.Clinical management of advanced gastric cancer: the role of new molecular drugs.Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery.Marked antitumor effect of NK012, a SN-38-incorporating micelle formulation, in a newly developed mouse model of liver metastasis resulting from gastric cancer.Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway.Suppressor of cytokine signaling 4 detected as a novel gastric cancer suppressor gene using double combination array analysis.The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.Systemic chemotherapy as a main strategy for liver metastases from gastric cancer.Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer.
P2860
Q26765314-4AA6424F-F002-418C-ACCF-479C1B6D67F2Q34766486-903215B3-258D-4CC9-81EC-07821077A32BQ35043996-558AD317-D475-4690-911F-00E7F4149D98Q35623065-398D3101-9B3A-46F4-8303-73403CCD4D4EQ36216766-2AA467EB-72BC-40E8-AD26-3051877DF412Q36398732-F5B3F73D-317E-4003-BCA1-6FAB4449AC9CQ37024025-704F5E89-DB19-4BE2-8D88-ECDC52AC20B2Q37035291-842D43B0-01FD-46D0-91A1-0689C0250BACQ37326072-A66DD693-D5E0-48B9-8EEB-8CD24CFB4370Q37330920-8D7855B3-95B1-4E7D-8FAE-CC48C5ACF03DQ37885725-18987709-B0E5-4A84-8821-6694CA29E4C5Q38177325-07A65B13-6712-410A-BB3B-DE910F3070CBQ38263841-C530A869-2B8B-4F1C-8201-7E38F7A572D5Q38989275-292D503F-0D22-4A79-9741-42FD10F8696AQ39028548-B947D6FF-EE3D-4DE8-B1B2-A267FE96C03EQ39109847-E8247177-8D8E-411D-903E-EB3B735692B1Q39399913-5D589F31-F937-4FC7-902D-F76487AECC4FQ39435653-BDC43B5F-535A-425B-819A-33A43F2362BFQ39636381-CB7DDE17-9D2A-4360-8670-2138C15DBEBAQ39990738-A4FA67A5-43B9-46D3-BD97-2E63FC7ABB65Q41644087-DAE2FA05-A881-4920-B254-EDA58F523052Q47564950-9F0F4D35-A0E1-4E3F-9F58-1AE4D1AD952EQ50449083-8B473674-F2A0-4322-B81C-48F69D8BE8E8Q54326192-EF69876C-13F0-4861-BF2E-25E4C81541BB
P2860
Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Molecular basis for sensitivit ...... derived from liver metastasis.
@ast
Molecular basis for sensitivit ...... derived from liver metastasis.
@en
type
label
Molecular basis for sensitivit ...... derived from liver metastasis.
@ast
Molecular basis for sensitivit ...... derived from liver metastasis.
@en
prefLabel
Molecular basis for sensitivit ...... derived from liver metastasis.
@ast
Molecular basis for sensitivit ...... derived from liver metastasis.
@en
P2093
P2860
P356
P1476
Molecular basis for sensitivit ...... derived from liver metastasis
@en
P2093
H Nakanishi
H Yokoyama
M Fujiwara
M Tatematsu
Y Mochizuki
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603459
P407
P577
2006-11-07T00:00:00Z